TH Theratechnologies Inc.

Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.

A live webcast of the event can be accessed and through the investor relations section of the Company’s website under ‘. An archive will also be available for 90 days following the conference.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at .



Investor Contact:
Elif McDonald
Senior Director, Investor Relations
 
1-438-315-8563   

Media Contact:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
 
1-514-336-7800
EN
02/08/2022

Underlying

THTheratechnologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Reports on its Annual Meeting of Shareholders MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies rend compte de son assemblée annuelle des actionnair...

Theratechnologies rend compte de son assemblée annuelle des actionnaires MONTRÉAL, 29 mai 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a rapporté les résultats du vote lors de son assemblée annuelle des actionnaires qui a eu lieu aujourd’hui en mode virtuel uniquement. Les actionnaires ont voté pour les divers candidats mentionnés ci-dessous en vue de leur élection au conseil d’administration de la Société pour un mandat d’un an, ont nommé KPMG s.r.l./S.E.N.C.R.L. à...

May 29, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Impo...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHI...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles do...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles données soulignant l’importance de prendre en charge l’excès de graisse viscérale abdominale chez les personnes vivant avec le VIH L’analyse réalisée dans le cadre de l’étude VAMOS met en évidence le lien entre l’excès de graisse viscérale abdominale et la diminution de la qualité musculaire Selon ce qu’on rapporte dans la série de cas, l’association de la tésamoréline à un agoniste des récepteurs du GLP-1 fonctionne. MONTRÉAL, 02 mai 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Sociét...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Provides Update on Sale Process

Theratechnologies Provides Update on Sale Process MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch